WEARABLES EN PACIENTES CON TUMORES NEUROENDOCRINOS GASTROENTEROPANCREATICOS METASTÁSICOS. ESTUDIO NETFIT.

[ 177 Lu]Lu-DOTA-TATE and [ 131 I]MIBG Phenotypic Imaging-Based Therapy in Metastatic/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center.

Prado-Wohlwend, Stefan; (...); Merino-Torres, Juan Francisco

Article. 10.3389/fendo.2022.778322. 2022

• 
• 
• 16

  

Comparison of psychological distress for breast, ovarian and colorectal cancer predisposition in a Spanish sample at high risk of hereditary cancer.

Costa-Requena, Gema; (...); Segura-Huerta, Angel

Article. 10.1097/CEJ.0000000000000734. 2022

Co-occurrence of germline pathogenic variants for different hereditary cancer syndromes in patients with Lynch syndrome.

Ferrer-Avargues R; (...); Soto JL

Article. 10.1002/cac2.12134. 2021

• 
• 
• 13

  

Lanreotide 120 mg every 28 days (LAN) in patients with locally advanced or metastatic pancreatic neuroendocrine tumors (panNET) in routine clinical practice in Iberia

Alonso-Gordoa, T.; (...); de La Cruz, G.

Meeting Abstract. 2022

Management of incidentally discovered appendiceal neuroendocrine tumors after an appendicectomy.

Muñoz de Nova JL; (...); Martin-Perez, Elena

Review. 10.3748/wjg.v28.i13.1304. 2022

• 
• 
• 17

  

Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions.

del Olmo-Garcia, Maria I.; (...); Merino-Torres, Juan F.

Article. 10.3390/cancers14030584. 2022

• 
• 
• 20

  

Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS).

Benavent M; (...); Gallego J

Article. 10.1186/s12955-021-01688-x. 2021

Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy

Capdevila J; (...); Pubul V

Article. 10.1093/oncolo/oyab041. 2022

• 
• 
• 6

  

Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families

Fonfria, M; (...); Martinez-Duenas, E

Article. 10.3390/jpm11060548. 2021

• 
• 4

  

Psychiatric symptoms in a Spanish sample with hereditary cancer risk.

Costa-Requena G; (...); Segura-Huerta Á

Article. 10.1007/s12687-022-00580-5. 2022

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms.

Del Olmo-Garcia MI; (...); Merino-Torres JF

Article. 10.3390/biomedicines9121810. 2021

• 
• 
• 11

  

Survey for neuroendocrine tumors'standard of care - A multidisciplinary pilot study in Spanish specialists

Sampedro-Nunez, M; (...); Capdevila, J

Meeting Abstract. 2021

Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study

Custodio, A; (...); Villabona, C

Article. 10.1007/s12094-021-02608-7. 2021

• 
• 
• 1